TY - JOUR
T1 - Resolution of benign and malignant sebaceous neoplasms, in a renal transplant patient treated with everolimus
AU - Donati, Michele
AU - Paolino, Giovanni
AU - Muscardin, Luca
AU - Panetta, Chiara
AU - Donati, Pietro
PY - 2017/2/1
Y1 - 2017/2/1
N2 - Nonmelanoma skin cancers are the most common malignancies in transplant recipients under immunosuppression; nevertheless, appendage tumors also may appear. The onset of several cutaneous neoplasms in transplant patients can cause deterioration in quality of life of these patients. A 62-year-old white woman patient developed several malignant and benign sebaceous neoplasms during an immunosuppressive treatment for a renal transplant. The genetic study showed a mutation in MSH6-eson 1 (c116G>A), without mutations in MLH1 gene and MSH2. A final diagnosis of multiple sebaceous tumors in an immuno-suppressed patient without Muir–Torre syndrome was made. The spreading of further cutaneous neoplasms led to a change in immunosuppression: namely, that clinicians suspended tacrolimus and add everolimus. After 2 months, all tumor lesions on the face and on the limbs have disappeared, and no further lesions occurred. Everolimus could represent a valid therapeutical treatment for transplant patients at high risk for cutaneous tumors. A genetic consult and a consequent study of the genetic profile should be performed on each of these patients, to avoid risks of recurrent cutaneous tumors and negative effects on the quality of life.
AB - Nonmelanoma skin cancers are the most common malignancies in transplant recipients under immunosuppression; nevertheless, appendage tumors also may appear. The onset of several cutaneous neoplasms in transplant patients can cause deterioration in quality of life of these patients. A 62-year-old white woman patient developed several malignant and benign sebaceous neoplasms during an immunosuppressive treatment for a renal transplant. The genetic study showed a mutation in MSH6-eson 1 (c116G>A), without mutations in MLH1 gene and MSH2. A final diagnosis of multiple sebaceous tumors in an immuno-suppressed patient without Muir–Torre syndrome was made. The spreading of further cutaneous neoplasms led to a change in immunosuppression: namely, that clinicians suspended tacrolimus and add everolimus. After 2 months, all tumor lesions on the face and on the limbs have disappeared, and no further lesions occurred. Everolimus could represent a valid therapeutical treatment for transplant patients at high risk for cutaneous tumors. A genetic consult and a consequent study of the genetic profile should be performed on each of these patients, to avoid risks of recurrent cutaneous tumors and negative effects on the quality of life.
KW - Cutaneous tumors
KW - Immunosuppressive therapies
KW - Muir-Torre syndrome
UR - http://www.scopus.com/inward/record.url?scp=85011397509&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85011397509&partnerID=8YFLogxK
U2 - 10.6002/ect.2014.0208
DO - 10.6002/ect.2014.0208
M3 - Article
C2 - 25924010
AN - SCOPUS:85011397509
VL - 15
SP - 100
EP - 102
JO - Current Alzheimer Research
JF - Current Alzheimer Research
SN - 1567-2050
IS - 1
ER -